RCKT
Rocket Pharmaceuticals Inc
NASDAQ: RCKT · HEALTHCARE · BIOTECHNOLOGY
$2.58
+5.31% today
Updated 2026-10-28
Market cap
$245.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.17
Dividend yield
—
52W range
$2 – $5
Volume
1.9M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-4.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$8.58
+232.56%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy5 Hold1 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.07x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -4.60 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-39.62M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-221.86M | $-245.59M | $-258.75M | $-223.12M | $123.21M |
| EPS | — | — | — | — | $-0.17 |
| Free cash flow | $-186.76M | $-211.39M | $-215.59M | $-190.45M | $-39.62M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-11 | WILSON, MARTIN | Sale | 75,364 | $3.40 |
| 2026-08-18 | WILSON, MARTIN | Sale | 631 | $3.38 |
| 2026-08-18 | SHAH, GAURAV | Sale | 2,293 | $3.38 |
Peer comparison
Smart narrative
Rocket Pharmaceuticals Inc trades at $2.58. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -4.60, it sits in the distress.
Frequently asked questions
What is Rocket Pharmaceuticals Inc's stock price?
Rocket Pharmaceuticals Inc (RCKT) trades at $2.58.
Is Rocket Pharmaceuticals Inc overvalued?
Rocket Pharmaceuticals Inc carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Rocket Pharmaceuticals Inc (RCKT)?
The 12-month analyst consensus target is $8.58, about 232.6% above the current $2.58. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Rocket Pharmaceuticals Inc's Altman Z-Score is -4.60, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-4.68%
Beta0.50
50D MA$3.19
200D MA$3.52
Shares out0.11B
Float0.09B
Short ratio—
Avg volume1.9M
Performance
1 week-3.89%
1 month+1.92%
3 months+42.69%
YTD+5.70%
1 year—
3 years—
5 years—